Litcius/Paper detail

Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells

Lucia Vincenzetti, Rachel Wong, Roberta Marzi, Barbara Guarino, Erin Stefanutti, Sneha Gupta, Laura E. Rosen, David M. Belnap, Wang Li, Yi-Pei Chen, Julia di Iulio, Amin A. Momin, Karen E. Tracy, Sharvari Deshpande, John M. Errico, Federico Giovannoni, Nicole Sprugasci, Alessia Peter, Lillian Seu, Daniel Cloutier, Chin H. Tay, Gyorgy Snell, Nadine Czudnochowski, Florian A. Lempp, Colin Havenar‐Daughton, Fabio Benigni, Antonio Lanzavecchia, Kosh Agarwal, Man‐Fung Yuen, Heiner Wedemeyer, Ed Gane, Ann M. Arvin, Davide Corti, Michael Schmid

2025Journal of Hepatology11 citationsDOI

Topics & Concepts

HBsAgMonoclonal antibodyVirologyAntibodyMonoclonalReceptorHepatitis B virusMolecular biologyMedicineChemistryImmunologyBiologyVirusInternal medicineHepatitis B Virus StudiesMonoclonal and Polyclonal Antibodies ResearchHepatitis Viruses Studies and Epidemiology
Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells | Litcius